Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis

Seminars in Oncology Nursing

Volumn 20, Issue 1, 2004, Pages 3-10

  Avritscher, Elenir B C ^a,b   Cooksley, Catherine D ^a,b   Elting, Linda S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Section of Health Services Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; FLUOROURACIL; METHOTREXATE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; META ANALYSIS; MOUTH DISEASE; MUCOSA INFLAMMATION; NURSE; NURSING; REVIEW; RISK FACTOR; TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING; COST OF ILLNESS; ECONOMICS; HEALTH CARE PLANNING; INCIDENCE; METHODOLOGY; MOUTH HYGIENE; MOUTH MUCOSA; NEOPLASM; NURSE ATTITUDE; NURSING ASSESSMENT; ONCOLOGY NURSING; PATIENT CARE PLANNING; QUALITY OF LIFE; RADIOTHERAPY; STATISTICS; STOMATITIS; UTILIZATION REVIEW;

ANTINEOPLASTIC AGENTS; COST OF ILLNESS; GASTROINTESTINAL DISEASES; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INCIDENCE; MOUTH MUCOSA; NEOPLASMS; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; ORAL HYGIENE; PATIENT CARE PLANNING; QUALITY OF LIFE; RADIOTHERAPY; RISK FACTORS; STOMATITIS;

EID: 85047691529     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.soncn.2003.10.002     Document Type: Article

References (45)

1. Sonis S.T. Mucositis as a biological process a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncology. 34:1998;39-43
2. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy a systematic literature review. Radiother Oncol. 66:2003;253-262
3. Murray J.C., Chiu J.K., Dorfman S.R., et al. Epiglottitis following preparation for allogeneic bone marrow transplantation. Bone Marrow Transplant. 6:1995;997-998
4. Ruescher T.J., Sodeifi A., Scrivani S.J., et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 82:1998;2275-2281
5. Elting L.S., Bodey G.P., Keefe B.H. Septicemia and shock syndrome due to viridans streptococci a case-control study of predisposing factors. Clin Infect Dis. 14:1992;1201-1207
6. Trotti A. Toxicity in head and neck cancer a review of trends and issues. Int J Radiat Oncol Biol Phys. 47:2000;1-12
7. Nicolaou N. Prevention and management of radiation toxicity. Pazdur R., Coia L.R., Hoskins W.J., Wagman L.D. Cancer Management A Multidisciplinary Approach. 2003;909-939 SCP Oncology, New York, NY
8. Maguire A., Welbury R.R. Long-term effects of antineoplastic chemotherapy and radiotherapy on dental development. Dent Update. 23:1996;188-194
9. Bellm L.A., Cunningham G., Durnell L., et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis oral mucositis patient provider advisory board. Cancer Invest. 20:2002;793-800
10. Elting L.S., Cooksley C., Chambers M., et al. The burdens of cancer therapy clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 98:2003;1531-1539
11. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 19:2001;2201-2205
12. Peterman A., Cella D., Glandon G., et al. Mucositis in head and neck cancer economic and quality-of-life outcomes. J Natl Cancer Inst Monogr. 29:2001;45-51
13. Sonis S.T., Sonis Al., Lieberman A. Oral complications in patients receiving treatment for malignancy other than the head and neck. J Am Dent Assoc. 97:1978;468-472
14. Cheng K.K.F., Molassiotis A., Chang A.M., et al. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer. 37:2001;2056-2063
15. Graham K.M., Pecoraro D.A., Ventura M., et al. Reducing the incidence of stomatitis using a quality assessment and improvement approach. Cancer Nurs. 16:1993;117-122
16. Sonis S.T., Fey E.G. Oral complications of cancer therapy. Oncology (Huntingt). 16:2002;680-686
17. Rocke L.K., Loprinzi C.L., Lee J.K., et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer. 72:1993;2234-2238
18. McCarthy G.M., Awde J.D., Ghandi H., et al. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol. 34:1998;484-490
19. Raber-Durlacher J.E., Weijl N.I., Abu Saris M., et al. Oral mucositis in patients treated with chemotherapy for solid tumors a retrospective analysis of 150 cases. Support Care Cancer. 8:2000;366-371
20. Balducci L., Extermann M. Management of cancer in the older person a practical approach. Oncologist. 5:2000;224-237
21. Fidler P., Loprinzini C.L., O'Fallon J.R., et al. Prospective evaluation of chamomile mouthwash for prevention of 5-fu-induced oral mucositis. Cancer. 77:1996;522-526
22. Okuno S.H., Woodhouse C.O., Loprinzi C.L., et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol. 22:1999;258-261
23. Sloan J.A., Loprizini C.L., Novotny P.J., et al. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol. 18:2000;412-420
24. Sloan J.A., Goldberg R.M., Sargent D.J., et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 20:2002;1491-1498
25. Peterson D.E., Minah G.E., Overholser C.D., et al. Microbiology of acute periodontal infection in myelosuppressed cancer patients. J Clin Oncol. 5:1987;1461-1468
26. Borowski B., Benhamou E., Pico J.L., et al. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol. 30B:1994;93-97
27. Raber-Durlacher J.E. Current practices for management of oral mucositis in cancer patients. Support Care Cancer. 7:1999;71-74
28. Berger A.M., Eilers J. Factors influencing oral cavity status during high-dose antineoplastic therapy a secondary data analysis. Oncol Nurs Forum. 25:1998;1623-1626
29. McGuire D.B. Mucosal tissue injury in cancer therapy. More than mucositis and mouthwash. Cancer Pract. 10:2002;179-191
30. Wilkes J.D. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 25:1998;538-551
31. Epstein J.B., Tsang A.H., Warkentin D., et al. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 94:2002;39-44
32. Pico J.L., Avila-Garavito A., Naccache P. Mucositis Its occurrence, consequences, and treatment in the oncology setting. Oncologist. 3:1998;446-451
33. Barbounis V., Koumakis G., Vassilomanolakis M., et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer. 9:2001;258-260
34. Rougier P., Bugat R., Douillard J.Y., et al. Phase ii study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 15:1997;251-260
35. Peterson D.E. Research advances in oral mucositis. Curr Opin Oncol. 11:1999;261-266
36. Hansen R.M., Ryan L., Anderson T., et al. Phase iii study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst. 88:1996;668-674
37. Anonymous. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-analysis group in cancer. J Clin Oncol. 16:1998;3537-3541
38. Codacci-Pisanelli G., Van der Wilt C.L., Smid K., et al. High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into rna in murine tumors. Oncology. 62:2002;363-370
39. Bellm L.A., Epstein J.B., Rose-Ped A., et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 8:2000;33-39
40. Hoekman K., Vermorken J.B. Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Ann Med. 28:1996;175-182
41. McGlave P.B., Shu X.O., Wen W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia 9 years' experience of the national marrow donor program. Blood. 95:2000;2219-2225
42. Rapoport A.P., Miller Watelet L.F., Linder T., et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 17:1999;2446-2453
43. National Institutes of Health Consensus Development Panel. Consensus statement Oral complications of cancer therapies. National Cancer Institute monographs. 1990;3-8 US Department of Health and Human Service, Public Health Service National Cancer Institute, Bethesda, MD
44. Zerbe M.B., Parkerson S.G., Ortlieb M.L., et al. Relationships between oral mucositis and treatment variables in bone marrow transplant patients. Cancer Nurs. 15:1992;196-205
45. Woo S.B., Sonis S.T., Monopoli M.M., et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 72:1993;1612-1617